Page last updated: 2024-12-09

bemethyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bemethyl: 2-mercaptobenzimidazole deriv.; alkylating agent and mutagen antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID720878
CHEMBL ID1559140
SCHEMBL ID7998438
MeSH IDM0142576
PubMed CID9816609
SCHEMBL ID2506425
MeSH IDM0142576

Synonyms (72)

Synonym
EU-0066795
BB 0219618
smr000152695
MLS000565609
IFLAB1_004378
DIVK1C_001227
CDS1_000187 ,
CBDIVE_003068
IDI1_010133
1h-benzimidazole, 2-(ethylthio)-
2-ethylsulfanyl-1h-benzimidazole
MAYBRIDGE1_002475
2-(ethylsulfanyl)-1h-benzimidazole
STK387530
AKOS000275365
HMS1424G22
2-(ethylthio)-1h-benzimidazole
F1011-0541
2-ethylsulfanyl-1h-benzoimidazole
14610-11-8
2-(ethylsulfanyl)-1h-1,3-benzodiazole
HMS2444B04
2-ethylthiobenzimidazole
SCHEMBL7998438
mfcd00223154
CHEMBL1559140
AE-641/00387012
2-mercaptoethylbenzimidazole
bemithyl
1h-benzimidazole,2-(ethylthio)-(9ci)
CCG-233314
sr-01000389082
SR-01000389082-1
DTXSID20352179
bemetil
bemythyl
Z53833332
Q4532987
2-(ethylthio)-1h-benzo[d]imidazole
AS-37719
CS-0074586
2S44TEQ96E ,
2-(ethylthio)benzimidazole
unii-2s44teq96e
EN300-92946
1h-1,3-benzimidazol-2-yl ethyl sulfide
2-ethylsulfanyl-1h-benzoimidazole; hydrobromide
BB 0242170
2-(ethylthio)-1h-benzo[d]imidazole hydrobromide
F1279-0006
SCHEMBL2506425
2-(ethylthio)-1h-benzimidazole hydrobromide
63513-71-3
DTXSID00212924
bemethyl
bemitil
2-ethylthiobenzimidazole hydrobromide
1h-benzimidazole, 2-(ethylthio)-, monohydrobromide
CS-0238217
2-ethylsulfanyl-1h-benzimidazole;hydrobromide
2-(ethylsulfanyl)-1h-1,3-benzodiazole hydrobromide
109628-14-0
betamyl
2-ethylsulfanyl-1h-benzimidazole hydrobromide
TG4SAK8A5M ,
metaprot
antihot
2-(ethylthio)benzimidazole hydrobromide
bemiton
unii-tg4sak8a5m
EN300-191482
2-(ethylsulfanyl)-1h-1,3-benzodiazolehydrobromide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The LD50 was estimated to be 330 mg/kg."( Toxicity study of a rubber antioxidant, mixture of 2-mercaptomethylbenzimidazoles, by repeated oral administration to rats.
Hasegawa, R; Hayashi, M; Inoue, T; Isama, K; Kawasaki, Y; Kitajima, S; Kurokawa, Y; Matsushima, Y; Momma, J; Ogawa, Y; Ohno, Y; Saitoh, M; Sakemi, K; Sofuni, T; Suzuki, T; Tsuda, M; Umemura, T, 1999
)
0.3
"The experiments on rats showed for bemithyl LD50 = 581."( [Acute toxicity of bemithyl and bromithyl].
Bugaeva, LI; Iezhitsa, IN; Spasov, AA; Verovskiĭ, VE,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" A high degree of correlation for some pharmacokinetic parameters of bemithil following the administration of the drug test dose and its global therapeutic effect was established."( [The role of bemitil pharmacokinetics in realizing its therapeutic efficacy].
Boĭko, SS; Neznamov, GG; Zherdev, VP,
)
0.13
" The two-compartment model was used for calculation of the main pharmacokinetic constants and bioavailability."( [Bemetil pharmacokinetics in an experiment on rats].
Bobkov, IuG; Boĭko, SS; Dvorianinov, AA; Zherdev, VP,
)
0.13
" The pharmacokinetic parameters were calculated by the model-independent method."( [Pharmacokinetics of domestic actoprotector drug Metaprot in healthy volunteers].
Belolipetskaia, VG; Blagodatskikh, SV; Iatsuk, VR; Kibal'chich, DA; Martsevich, SIu; Rudenko, LI, 2011
)
0.37
" The main drug metabolites were identified and the pharmacokinetic parameters were calculated."( [Features of bemithyl pharmacokinetics upon inhalation administration].
Bykov, VN; Geĭbo, DS; Kurpiakova, AF; Nikiforov, AS, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" The obtained results suggest that the inhalation administration of bemithyl is a promising replacement for oral administration, which is related to high bioavailability of the drug and the absence of the effect of "first pass" through the liver."( [Features of bemithyl pharmacokinetics upon inhalation administration].
Bykov, VN; Geĭbo, DS; Kurpiakova, AF; Nikiforov, AS, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
PINK1Homo sapiens (human)Potency28.18382.818418.895944.6684AID624263
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency3.98110.28189.721235.4813AID2326
ParkinHomo sapiens (human)Potency28.18380.819914.830644.6684AID624263
Glycoprotein hormones alpha chainHomo sapiens (human)Potency2.81844.46688.344810.0000AID624291
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency10.00001.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (7.94)18.7374
1990's23 (36.51)18.2507
2000's17 (26.98)29.6817
2010's15 (23.81)24.3611
2020's3 (4.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.33 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index61.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials10 (10.99%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
Other81 (89.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]